Clinical Trial Update: Outcomes of Once-Daily ICS/LABA/LAMA + PRN Respiratory Therapy Treatments in Hospitalized Patients With COPD Exacerbations [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating outcomes of once-daily triple inhaled therapy (ICS/LABA/LAMA) plus PRN respiratory therapy in hospitalized COPD patients with exacerbat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease
• Exacerbation of Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol)

Snippet

Sponsor: Baylor Research Institute | Conditions: Copd | Phase 4 | Status: COMPLETED | Results posted: 2025-11-21